GLYR1 (glyoxylate reductase 1 homolog) is a chr16-binding epigenetic reader and nucleosome-destabilizing factor that regulates gene expression through multiple mechanisms 12. It binds histone H3 and DNA without sequence specificity, and forms a functional complex with histone demethylase KDM1B to facilitate H3K4 demethylation and stimulate H3K56 acetylation, thereby enhancing transcription elongation through nucleosomes 13. During cardiomyocyte differentiation, GLYR1 co-occupies and co-activates cardiac developmental genes with transcription factor GATA4 4. GLYR1 also regulates p38 MAPK signaling by promoting MAPK14 phosphorylation and ATF2 activation 5. Clinically, GLYR1 mutations associate with congenital heart disease through disrupted GATA4 interaction 4. GLYR1 is frequently mutated in microsatellite-unstable colorectal cancer, where its downregulation promotes cell proliferation and reduces chemotherapy sensitivity via p38MAPK and PI3K/AKT pathways 67. In multiple myeloma and breast cancer, GLYR1 acts as an oncogenic transcription factor, upregulating PER3 to suppress myeloma progression or downregulating lncRNA HSD11B1-AS1 to promote breast cancer malignancy 89. GLYR1 fusion genes also drive myelodysplastic/myeloproliferative neoplasms 10. These divergent roles suggest tissue and context-dependent functions in both tumor suppression and oncogenic pathways.